Key result
COVID-19 mRNA vaccine hesitancy in Italy is driven by public perplexity regarding vaccine efficacy and adverse effects, necessitating thorough elucidation of clinical trial data.
This commentary addresses vaccine hesitancy, efficacy, and safety concerns regarding mRNA-based COVID-19 vaccines in Italy.
Coronavirus disease 2019 (COVID-19) vaccination campaign in Italy has started with a huge perplexity about vaccine efficacy, vaccine-borne adverse effects and vaccine clinical trial studies. In this commentary I tried to elucidate these issues, which represent a fundamental topic to be thoroughly addressed in COVID-19 pandemic.
No takes yet. Share an insight, caveat, or question.
Salvatore Chirumbolo (2021) studied this question. COVID-19 mRNA vaccine hesitancy in Italy is driven by public perplexity regarding vaccine efficacy and adverse effects, necessitating thorough elucidation of clinical trial data.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: